Scholar Rock (SRRK)
(Real Time Quote from BATS)
$8.80 USD
-0.65 (-6.88%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $8.82 +0.02 (0.23%) 4:16 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Scholar Rock Holding Corporation [SRRK]
Reports for Purchase
Showing records 61 - 80 ( 124 total )
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Scholar Rock is Decoding TGF-a Signaling to Unlock its Untapped Therapeutic Power; Initiate at Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Apitegromab Leaves No Stone Unturned at MDA 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
KOL is Buzzing for Apitegromab?s Potential in SMA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D